nach oben

Erschienen in:

01.08.2013 | Original Article

ISPMD consensus on the management of premenstrual disorders

verfasst von: Tracy Nevatte, Patrick Michael Shaughn O’Brien, Torbjorn Bäckström, Candace Brown, Lorraine Dennerstein, Jean Endicott, C. Neill Epperson, Elias Eriksson, Ellen W. Freeman, Uriel Halbreich, Khalid Ismail, Nicholas Panay, Teri Pearlstein, Andrea Rapkin, Robert Reid, David Rubinow, Peter Schmidt, Meir Steiner, John Studd, Inger Sundström-Poromaa, Kimberly Yonkers, Consensus Group of the International Society for Premenstrual Disorders

Erschienen in: Archives of Women's Mental Health | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The second consensus meeting of the International Society for Premenstrual Disorders (ISPMD) took place in London during March 2011. The primary goal was to evaluate the published evidence and consider the expert opinions of the ISPMD members to reach a consensus on advice for the management of premenstrual disorders. Gynaecologists, psychiatrists, psychologists and pharmacologists each formally presented the evidence within their area of expertise; this was followed by an in-depth discussion leading to consensus recommendations. This article provides a comprehensive review of the outcomes from the meeting. The group discussed and agreed that careful diagnosis based on the recommendations and classification derived from the first ISPMD consensus conference is essential and should underlie the appropriate management strategy. Options for the management of premenstrual disorders fall under two broad categories, (a) those influencing central nervous activity, particularly the modulation of the neurotransmitter serotonin and (b) those that suppress ovulation. Psychotropic medication, such as selective serotonin reuptake inhibitors, probably acts by dampening the influence of sex steroids on the brain. Oral contraceptives, gonadotropin-releasing hormone agonists, danazol and estradiol all most likely function by ovulation suppression. The role of oophorectomy was also considered in this respect. Alternative therapies are also addressed, with, e.g. cognitive behavioural therapy, calcium supplements and Vitex agnus castus warranting further exploration.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington: The Association

Andersch B, Wendestam C, Hahn L, Ohman R (1986) Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 5:39–49CrossRef

Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T (2009) Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 34:1121–32PubMedCrossRef

Angst J, Sellaro R, Merikangas KR, Endicott J (2001) The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104:110–16PubMedCrossRef

Bäckström T, Boyl H, Baird DT (1981) Persistence of symptoms of premenstrual tension in hysterectomized women. Br J Obstet Gynaec 88:530–536CrossRef

Bäckström T, Sanders D, Leask RM, Davidson D, Warner P, Bancroft J (1983) Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom Med 45:503–7PubMed

Bäckström T, Hansson-Malmström Y, Lindhe BA, Cavalli-Björkman B, Nordenström S (1992) Contraception 46:253–268PubMedCrossRef

Bäckström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S, Andréen L, Ossewaarde L, Wingen GA, Turkmen S, Bengtsson SK (2011) Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191:46–54PubMedCrossRef

Baker LJ, O’Brien PMS (2012) Potential strategies to avoid progestogen-induced premenstrual disorders. Menopause Int 18:73–76PubMedCrossRef

Björn I, Sundstrom-Poromaa I, Bixo M, Nyberg S, Backstrom G, Backstrom T (2003) Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88:2026–30PubMedCrossRef

Borenstein JE, Dean BB, Yonkers KA, Endicott J (2007) Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 109:1068–75PubMedCrossRef

Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL (1994) Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84:779–86PubMed

Brown J, O’Brien PMS, Marjoribanks J, Wyatt K (2009) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2, CD001396PubMed

Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH (2009) Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom 78:6–15PubMedCrossRef

Casper RF, Hearn MT (1990) The effect of hysterectomy and bilateral oophorectomy on women with severe premenstrual syndrome. Am J Obstet Gynecol 162:105–9PubMedCrossRef

Casson P, Hahn PM, Van Vugt DA, Reid RL (1990) Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 162:99–105PubMedCrossRef

Chan AF, Mortola JF, Wood SH, Yen SS (1994) Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 84:1001–1005PubMed

Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL (2002a) Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 70:125–32PubMedCrossRef

Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S (2002b) Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100:435–444PubMedCrossRef

Cronje WH, Vashisht A, Studd JW (2004) Hyseterctomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 19:2152–5PubMedCrossRef

Daley A (2009) Exercise and premenstrual symptomatology: a comprehensive review. J Women Health (Larchmt) 18:895–9CrossRef

Dante G, Facchinetti F (2011) Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 32:42–51PubMedCrossRef

Deeny M, Hawthorn R, McKay HD (1991) Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J 67:450–454PubMedCrossRef

Dennerstein L, Lehert P, Keung LS, Pal S, Choi D (2010a) Asian study of effects of premenstrual symptoms on activities of daily life. Menopause Int 16:146–151PubMedCrossRef

Dennerstein L, Lehert P, Bäckström TC, Heinemann K (2010b) The effect of premenstrual symptoms on activities of daily life. Fertil Steril 94:1059–64PubMedCrossRef

Dennerstein L, Lehert P, Heinemann K (2011) Global study of women’s experiences of premenstrual symptoms and their effects on daily life. Menopause Int 17:88–95PubMedCrossRef

Deuster P, Adera T, South-Paul J (1999) Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8:122–28PubMedCrossRef

Dimmock PW, Wyatt KM, Jones PW, O'Brien PM (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome; a systematic review. Lancet 356:1131–6PubMedCrossRef

Elovainio M, Teperi J, Aalto AM (2007) Depressive symptoms as predictors of discontinuation of Levonorgestrel releasing intrauterine system. Int J Behav Med 14:70–5PubMedCrossRef

Endicott J, Nee J, Harrison W (2006) Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 9:41–9PubMedCrossRef

Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, Weiss E, Rothman DL, Krystal JH (2002) Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psych 59:851–8CrossRef

Epperson CN, Steiner M, Hartlage SA, Eriksoon E, Schmidt P, Jones I, Yonkers KA (2012) Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psych 169:465–75

Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995) The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12:167–76PubMedCrossRef

Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson UB, Nissbrandt H (2008) Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28:195–202PubMedCrossRef

Freeman EW, Sondheimer SJ, Rickels K (1997) Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 33:303–9PubMed

Freeman EW, Rickels K, Sondheimer SJ, Polansky M (1999) Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56:932–9PubMedCrossRef

Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M (2001) Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10:561–9PubMedCrossRef

Freeman EW, Stout AL, Endicott J, Spiers P (2002) Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynaecol Obstet 77:253–54PubMedCrossRef

Freeman EW, Sammel MD, Lin H, Rickels K, Sondheimer J (2011) Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol 118:1293–1300PubMedCrossRef

Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD (2012) An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 85:437–45PubMedCrossRef

Graham CA, Sherwin BB (1992) A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36:257–66PubMedCrossRef

Hahn PM, Van Vugt DA, Reid RL (1995) A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 20:193–209PubMedCrossRef

Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L (2002) Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100:1219–1229PubMedCrossRef

Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(suppl 3):1–23

Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, Smith L, Mirkin S, Constantine GD (2012) Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 85:19–27PubMedCrossRef

Hammarbäck S, Bäckström T (1988) Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67:159–66PubMedCrossRef

Hammarbäck S, Bäckström T (1989) A demographic study in subgroups of women seeking help for premenstrual syndrome. Acta Obstet Gynecol Scand 68:247–53PubMedCrossRef

Hartlage SA, Freels A, Gotman N, Yonkers KA (2012) Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry 69(3):300–5PubMedCrossRef

Howland RH (2007) Managing common side effects of SSRIs. Psychopharm 45:15–18

Hunter MS, Ussher JM, Cariss M, Browne S, Jelley R, Katz M (2002) Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 53:811–7PubMedCrossRef

Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PM (1992) Buserelin in premenstrual syndrome. Gynecol Endocrinol 6:57–64PubMedCrossRef

Johnson SR, McChesney C, Bean JA (1988) Epidemiology of premenstrual symptoms in a nonclinical sample—I: prevalence, natural history and help-seeking behavior. J Repro Med 33:340–46

Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR (2009) Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet 105:158–61PubMedCrossRef

Kurshan N, Epperson CN (2006) Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Women Ment Health 9:1–14CrossRef

Länden M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E (2007) Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32:153–61PubMedCrossRef

Leather AT, Studd JWW, Watson NR, Holland EFN (1999) The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo controlled study. Gynecol Endocrinol 13:48–55PubMedCrossRef

Lopez LM, Kaptein AA, Helmerhorst FM (2009) Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. (2):CD006586

Lustyk MK, Gerrish WG, Shaver S, Keys SL (2009) Cognitive–behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Women Ment Health 12:85–96CrossRef

Magos AL, Brincat M, Studd JWW (1986) Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral noresthisterone: placebo controlled study. BMJ 292:1629–33PubMedCrossRef

Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232:1004–1007PubMedCrossRef

Mellon SH (1994) Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab 78:1003–8PubMedCrossRef

Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M (1994) Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 62:932–7PubMed

Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002) Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24:417–433PubMedCrossRef

Mitwally MF, Gotlieb L, Casper RF (2002) Prevention of bone loss and hypestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9:236–41PubMedCrossRef

Moret C, Isaac M, Briley M (2009) Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharm 23:967–974CrossRef

Muse KN, Cetel NS, Futterman LA, Yen SC (1984) The premenstrual syndrome. Effects of "medical ovariectomy". N Engl J Med 311:1345–9PubMedCrossRef

Nurnberg HG (2008) An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today 44:147–68PubMedCrossRef

O’Brien PMS, Abukhalil IEH (1999) Randomised controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase only danazol. Am J Obstet Gynecol 180:18–23PubMedCrossRef

O’Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Neill et al (2011) Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD consensus. Arch Women Ment Health 14:13–21CrossRef

Oinonen KA, Mazmanian D (2002) To what extent do oral contraceptives influence mood and affect? J Affect Disord 70:229–40PubMedCrossRef

Olsen RW, Sieghart W (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141–8PubMedCrossRef

Parry BL, Meliska CJ, Martínez LF, López AM, Sorenson DL, Hauger RL, Elliott JA (2008) Later, but not early, wake therapy reduces morning plasma melatonin: relationship to mood in premenstrual dysphoric disorder. Psychiatry Res 30:76–86CrossRef

Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA (1997) Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17:261–6

Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72:414–21

Pincus SM, Alam S, Rubinow DR, Bhuvaneswar CG, Schmidt PJ (2011) Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res 45:386–94PubMedCrossRef

Ramacharan S, Love EJ, Fick GH, Goldfien A (1992) The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 45:377–81CrossRef

Rivera-Tovar AD, Frank E (1990) Late luteal phase dysphoric disorder in young women. Am J Psychiatry 147:1634–36PubMed

Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U (2011) Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health 8:2PubMedCrossRef

Royal College of Obstetricians and Gynaecologists (RCOG) (2007) Management of Premenstrual Syndrome (Green-top Guideline No. 48). http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT48ManagementPremensturalSyndrome.pdf. Accessed 10 May 2009

Sanders SA, Graham CA, Bass JL, Bancroft J (2001) A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64:51–8PubMedCrossRef

Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R (1995) The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 86:520–8PubMed

Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR (1991) Lack on effect of induced menses of symptoms on women with premenstrual syndrome. N Engl J Med 324:1174–1179PubMedCrossRef

Schmidt PJ, Grover GN, Rubinow DR (1993) Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 50:467–73PubMedCrossRef

Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338:209–16PubMedCrossRef

Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I (2009) Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol 201:139, e1-8PubMedCrossRef

Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borensstein J (2008) Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 111:1175–1182PubMedCrossRef

Shechter A, Boivin DB (2010) Sleep, hormones, and circadian rhythms throughout the menstrual cycle in healthy women and women with premenstrual dysphoric disorder. Int J Endocrinol 2010:259345PubMed

Smith RNH, Studd JWW, Zamblera D, Holland EFN (1995) A randomised comparison over 8 months of 100 mcgs and 200 mcg twice weekly doses in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 102:6475–84

Soares C, Cohen L, Otto M, Harlow B (2001) Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard study of moods and cycles. J Women’s Health Gend Based Med 10:873–78CrossRef

Steiner M, Pearlstein T (2000) Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 61(Suppl 12):17–21PubMed

Steiner M, Macdougall M, Brown E (2003) The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 6:203–209CrossRef

Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN (2011) The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Women Ment Health 14:77–81CrossRef

Studd J (2011) A guide to the treatment of depression women by hormones. Climacteric 14:637–42PubMedCrossRef

Sundblad C, Hedberg MA, Eriksson E (1993) Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9:133–145PubMedCrossRef

Sundstrom I, Nyberg S, Bixo M, Hammarbäck S, Bäckström T (1999) Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 78:891–9PubMedCrossRef

Sveindóttir H, Bäckström T (2000) Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79:405–13PubMedCrossRef

Thys-Jacobs S, Starkey P, Bernstein D, Tian J (1998) Calcium carbonate and the premenstrual syndrome: effects of premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group Am J Obstet Gynecol 179:444–52CrossRef

Watson NR, Studd JWW, Savvas M, Garnett T, Baber RJ (1989) Treatment of severe pre-menstrual syndrome with estradiol patched and cyclical oral noresthisterone. Lancet ii:730–734CrossRef

West CP, Hillier H (1994) Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 9:1058–63PubMed

Whelan AM, Jurgens TM, Naylor H (2009) Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 16:407–29

Wittchen HU, Becker E, Lieb R, Krause P (2002) Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32:119–132PubMedCrossRef

Woods NF, Most A, Dery GK (1982) Prevalence of perimenstrual symptoms. Am J Public Health 72:1257–64PubMedCrossRef

Wyatt KM, Dimmock PW, Jones PW, O’Brien PMS (1999) Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318:1375–81PubMedCrossRef

Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM (2004) The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta-analysis. BJOG 111:585–93PubMedCrossRef

Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492–501PubMedCrossRef

Yonkers KA, O’Brien PMS, Eriksson E (2008) Premenstrual syndrome. Lancet 371:1200–10PubMedCrossRef

Titel: ISPMD consensus on the management of premenstrual disorders
verfasst von: Tracy Nevatte
Patrick Michael Shaughn O’Brien
Torbjorn Bäckström
Candace Brown
Lorraine Dennerstein
Jean Endicott
C. Neill Epperson
Elias Eriksson
Ellen W. Freeman
Uriel Halbreich
Khalid Ismail
Nicholas Panay
Teri Pearlstein
Andrea Rapkin
Robert Reid
David Rubinow
Peter Schmidt
Meir Steiner
John Studd
Inger Sundström-Poromaa
Kimberly Yonkers
Consensus Group of the International Society for Premenstrual Disorders
Publikationsdatum: 01.08.2013
Verlag: Springer Vienna
Erschienen in: Archives of Women's Mental Health / Ausgabe 4/2013
Print ISSN: 1434-1816
Elektronische ISSN: 1435-1102
DOI: https://doi.org/10.1007/s00737-013-0346-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

ISPMD consensus on the management of premenstrual disorders

Abstract

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Gender differences in health-related quality of life in patients with bipolar disorder

Postpartum depression symptoms associated with Val158Met COMT polymorphism

Exposure to environmental tobacco smoke and risk of antenatal depression: application of latent variable modeling

A Guide for the Statistically Perplexed: Selected Readings for Clinical Researchers

Cognitive–behavioral group treatment for menopausal symptoms: a pilot study

Characteristics of perinatal women seeking treatment for marijuana abuse in a community-based clinic

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko